<DOC>
	<DOCNO>NCT01313819</DOCNO>
	<brief_summary>Tp determine effect IV amantadine dopaminergic-drug-resistant freeze gait ( FOG ) patient Parkinson ` disease</brief_summary>
	<brief_title>The Effect IV Amantadine Freezing Gait ( FOG ) Resistant Dopaminergic Therapy</brief_title>
	<detailed_description>1 . Freezing gait ( FOG ) one disabling symptom Parkinson ` disease . We experience severe FOG markedly improve IV amantadine patient Parkinson ` disease . But IV drug may placebo effect . Therefore , We design double blind , placebo control study know whether IV amantadine effective patient dopaminergic-drug-resistant freezing gait ( FOG ) . 2 . Cross study design - Compare change FOGQ ( freeze gait questionaire ) score baseline IV amantadine placebo drug - randomize assigned order amantadine placebo drug . - investigator FOG : blind order drug - patient IV drug 2 day drug</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Inclusion Criteria age : 3080 year idiopathic Parkinson 's disease The patient must take optimised levodopa/DDI therapy ( base investigator 's judgement ) OPD observation period , though patient FOGQ score â‰¥ 10 point even though Onstate . `` Off '' freezing : The patient improve FOG `` On '' state clinically significant unstable medical surgical condition The patient Parkinson plus like MSA , PSP , PPFG , secondary parkinsonism like NPH , vascular parkinsonism , postencephalitic parkinsonism , CO poison . history seizure .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Freezing</keyword>
</DOC>